Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Assets: 2020-2024

Historic Assets for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $1.0 billion.

  • Maravai Lifesciences Holdings' Assets fell 33.57% to $849.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $849.2 million, marking a year-over-year decrease of 33.57%. This contributed to the annual value of $1.0 billion for FY2024, which is 32.22% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Assets stood at $1.0 billion for FY2024, which was down 32.22% from $1.5 billion recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year Assets high stood at $2.3 billion for FY2022, and its period low was $1.0 billion during FY2024.
  • For the 3-year period, Maravai Lifesciences Holdings' Assets averaged around $1.6 billion, with its median value being $1.5 billion (2023).
  • In the last 5 years, Maravai Lifesciences Holdings' Assets surged by 50.96% in 2021 and then tumbled by 34.83% in 2023.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Assets stood at $1.3 billion in 2020, then skyrocketed by 50.96% to $1.9 billion in 2021, then increased by 18.98% to $2.3 billion in 2022, then slumped by 34.83% to $1.5 billion in 2023, then crashed by 32.22% to $1.0 billion in 2024.